TImeline
2016
6.1.2016
Octeta Therapeutics formed by MSDC to advance the clinical development of MSDC-0602K, a new therapeutic compound currently in a Phase 2 clinical trial (the EMMINENCE™ Trial) for the treatment of nonalcoholic steatohepatitis (NASH).
2015
2015
3.18.2015
Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease
2014
10.23.2014
Metabolic Solutions Development Company Appoints Robert L. Zerbe, MD to Board of Managers
2013
9.24.2013
Researchers present findings on key proteins in newly identified target for insulin sensitizers
9.19.2013
Investigational Diabetes Drug May Also Have Future As Treatment for Parksinson’s Disease
9.9.2013
Metabolic Solutions Development Company presents Phase 2a clinical trial results at the 14th International Conference on Alzheimer’s Drug Discovery
5.29.2013
Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
5.15.2013
Metabolic Solutions Development Company announces publication of data describing a new drug target for diabetes
2.7.2013
Metabolic Solutions Development Company Awarded Funding by The Michael J. Fox Foundation
1.24.2013
Metabolic Solutions Development Company announces publication of Phase 2b data in “Clinical Pharmacology & Therapeutics”
2012
2012
10.17.2012
Metabolic Solutions Development Company CEO Stephen Benoit to Present at 2nd Annual BIO Convention in China (BIO China to be held October 24-25 in Shanghai)
10.2.2012
Researchers present findings on new drug target for treatment of type 2 diabetes
9.7.2012
Metabolic Solutions Development Company Presents Update on Ongoing Clinical Evaluation of First in Class mTOT Modulator™ in Mild Alzheimer’s Disease at 13th International Conference on Alzheimer’s Drug Discovery
8.29.2012
Metabolic Solutions Development Company to present at the Benzon Symposium No. 58 on Adipose Tissue in Health and Disease
6.21.2012
Researchers study potential new therapeutic target for Alzheimer’s disease. Medical centers in Kalamazoo and Grand Rapids referring individuals for participation in a clinical trial.
6.9.2012
Metabolic Solutions Development Company Identifies New Drug Target for Treatment of Type 2 Diabetes
6.9.2012
Metabolic Solutions Development Company Novel Insulin Sensitizer Meets Phase 2b Study Endpoints and Affirms New Mechanism of Action
5.29.2012
New Research Suggests Novel Insulin Sensitizer Works Through a New Mechanism to Treat Root Cause of Type 2 Diabetes
4.11.2012
Metabolic Solutions Development Company Adds Barbara Cannon to Science and Medical Advisory Board
3.8.2012
Metabolic Solutions Development Company presents Case Study: A new approach to insulin sensitizers during Phacilitate-Metabolic Leaders Forum 2012
2.9.2012
Researchers Study Mitochondrial Function, Potential New Therapeutic Target for Alzheimer’s Disease
1.31.2012
Metabolic Solutions Development Company previews latest findings on newly identified potential mechanism of action for insulin sensitization at Keystone Symposium on Pathogenesis of Diabetes: Emerging Insights into Molecular Mechanisms
2011
12.1.2011
Metabolic Solutions Development Company, LLC to present at Windhover’s 6th annual Therapeutic Area Partnerships meeting
11.17.2011
Metabolic Solutions Jandernoa Receives Spirit of Michigan Award
10.6.2011
Metabolic Solutions Development Company Receives $1.1 Million NIH Grant to Further Investigate MSDC-0602 for the Treatment of Fatty Liver Disease
9.8.2011
Metabolic Solutions Development Company presents new brown fat research at the European Association for the Study of Diabetes
9.8.2011
Metabolic Solutions Development Company Reports Positive Top-Line Results From 2a Trial of its Second Compound to Treat Type 2 Diabetes
7.6.2011
Metabolic Solutions Development Company Receives $773,000 From Alzheimers Drug Discovery Foundation To Fund Phase 2a Trial
6.21.2011
MSDC to Present Recent Findings at American Diabetes Association Conference
3.29.2011
Metabolic Solutions Development Company Launches Phase 2a Trial of its Second Compound to Treat Type 2 Diabetes
3.7.2011
Metabolic Solutions Development Company President and Co-Founder to Speak at Diabetes Summit
2010
10.21.2010
Metabolic Solutions Development Company Raises Approximately $23.5 Million; Plans to Launch Phase 2b Trial
9.16.2010
Metabolic Solutions Development Company to Present Research Findings to European Association for the Study of Diabetes
6.15.2010
Metabolic Solutions Development Company to Present Research Findings at Annual American Diabetes Association Conference
4.8.2010
Metabolic Solutions Development Company Named One of 50 Michigan Companies to Watch
2009
10.12.2009
Metabolic Solutions Development Company To Test Potential Treatment For Alzheimer’s.
5.14.2009
Metabolic Solutions Development Company announces preliminary results from Phase IIa clinical trial.
4.29.2009
Metabolic Solutions Development Company secures more than $10 Million for further development of its diabetes drug portfolio.
2008
9.30.2008
West Michigan drug research company set to begin major clinical trial of diabetes drug
5.28.2008
Dr. John Landis joins Board of Managers of Metabolic Solutions Development Coes.